vaccin
prevent
treatment
option
avail
year
proven
effect
prevent
infect
previous
high
morbid
mortal
exampl
erad
small
pox
mainli
attribut
success
vaccin
program
prevent
high
burden
diseas
sinc
proven
cost
effect
measur
vaccin
becom
part
multipl
nation
health
program
promis
result
led
develop
vaccin
studi
applic
field
cancer
prevent
treatment
vaccin
drug
administ
healthi
individu
much
like
drug
vaccin
associ
advers
event
usual
describ
advers
event
transient
acut
may
rare
present
hypersensit
induct
autoimmun
may
sever
fatal
advers
event
play
import
role
life
vaccin
patient
immun
mediat
diseas
aris
variou
differ
sourc
includ
environment
genet
hormon
immun
defect
combin
defect
describ
mosaic
autoimmun
patient
background
use
clue
determin
respons
may
elicit
follow
drug
administr
proven
infecti
agent
may
elicit
autoimmun
diseas
prone
subject
variou
mechan
includ
limit
molecular
mimicri
epitop
spread
polyclon
activ
scientif
find
suggest
autoimmun
may
trigger
vaccin
adjuv
aluminum
compound
aluminum
hydroxid
phosphat
studi
wide
use
adjuv
molecul
combin
antigen
enhanc
immunolog
respons
enabl
easier
effect
recognit
non
self
turn
permit
trigger
adapt
innat
immun
respons
recent
new
syndrom
describ
autoimmuneinflammatori
syndrom
induc
adjuv
asia
embodi
spectrum
reaction
usual
mild
may
also
sever
reaction
attribut
adjuv
stimul
includ
chronic
exposur
silicon
tetramethylpentadecan
pristan
aluminum
infecti
compon
adjuv
environment
factor
found
induc
autoimmun
inflammatori
manifest
anim
model
human
mechan
diseas
describ
detail
review
focu
gener
mechan
vaccin
adjuvantinduc
autoimmun
vaccin
specif
autoimmun
diseas
may
trigger
adjuv
approv
date
human
vaccin
aluminum
viral
vaccin
mpl
viral
parasit
infect
virosom
hepat
b
viru
hbv
human
papilloma
viru
hpv
hepat
viru
hav
cholera
toxin
cholera
adjuv
may
compos
sever
differ
compound
current
oil
base
adjuv
virosom
tolllik
receptor
tlr
relat
adjuv
mpl
adjuv
made
unmethyl
cpg
dinucleotid
tuftsin
describ
great
interest
understand
mechan
relat
adjuv
effect
well
aluminum
salt
aluminum
act
multipl
pathway
depend
sole
tlr
signal
pathway
lead
enhanc
host
immun
respons
mani
oil
base
adjuv
one
incomplet
freund
adjuv
ifa
contain
water
oil
emuls
anoth
complet
freund
adjuv
cfa
ifa
except
also
contain
kill
mycobacteria
addit
water
oil
emuls
usual
cfa
use
primari
vaccin
ifa
boost
recent
oil
base
adjuv
develop
novarti
glaxosmithklin
advax
tm
base
inulin
compound
vaxin
tm
pti
immun
stimul
complex
compos
cholesterol
phospholipid
without
antigen
tabl
virosom
adjuv
contain
membranebound
hemagglutinin
neuraminidas
obtain
influenza
viru
compon
facilit
uptak
antigen
present
cell
apc
mimic
natur
immun
respons
leucocyt
membran
membran
bound
pattern
recognit
receptor
prr
call
tlr
respons
detect
although
certainli
antigenmedi
infect
activ
lead
adapt
immun
respons
reason
mani
adjuv
use
today
direct
prr
adjuv
call
tlr
relat
adjuv
mpl
seri
lipid
obtain
purif
modifi
lipopolysaccharid
lp
salmonella
minnesota
bacteri
deoxyribonucl
acid
dna
immunostimulatori
due
unmethyl
cpg
dinucleotid
vertebr
dna
rel
low
amount
unmethyl
cpg
compar
bacteri
dna
adjuv
effect
cpg
enhanc
conjug
protein
antigen
adjuv
test
vaccin
direct
infecti
agent
allergen
tumor
cell
anoth
type
adjuv
tuftsin
tuftsin
auto
adjuv
natur
selfimmunostimul
tetrapeptid
thrlysproarg
tetrapeptid
fraction
igg
heavi
chain
molecul
produc
enzymat
cleavag
spleen
function
includ
bind
receptor
neutrophil
macrophag
stimul
phagocyt
activ
increas
tumor
necrosi
factor
alpha
releas
human
kupffer
cell
enhanc
secret
activ
macrophag
activ
macrophag
express
nitric
oxid
synthas
produc
enhanc
murin
natur
cell
mediat
cytotox
vitro
summari
adjuv
minor
side
effect
promis
effect
restor
innat
immun
mediat
respons
adjuv
may
exert
immun
enhanc
effect
accord
five
immun
function
activ
transloc
antigen
lymph
node
recogn
cell
antigen
protect
enabl
longer
exposur
enhanc
local
reaction
inject
site
induct
releas
inflammatori
cytokin
interact
prr
specif
tlr
adjuv
effect
term
adjuv
effect
refer
coadministr
antigen
microbi
specif
factor
enhanc
antigenspecif
immun
respons
vivo
microbi
compon
adjuv
activ
apc
produc
proinflammatori
cytokin
nonspecif
signal
upregul
molecul
essenti
antigen
present
molecul
includ
major
histocompat
complex
mhc
class
ii
antigenspecif
signal
innat
immun
event
allow
effect
present
adapt
immun
system
result
augment
activ
clonal
expans
cell
accord
effect
selfantigen
use
autoimmun
respons
elicit
shown
autoreact
tcell
surpass
toler
mechan
trigger
exogen
adjuv
becom
autoaggress
infecti
agent
abl
natur
gener
adjuv
effect
induc
autoimmun
exampl
causal
viral
infect
myocard
half
case
myocard
preced
acut
viral
infect
infecti
myocard
human
reproduc
experiment
murin
model
myocard
also
shown
autoimmun
reaction
elicit
infecti
agent
effect
treat
cancer
exampl
bladder
administr
bcg
bacil
shown
effect
superfici
bladder
cancer
develop
infer
adjuv
effect
use
specif
tumor
deriv
molecul
molecul
recogn
non
self
prrpamp
pattern
recognit
receptorpathogenassoci
molecular
pattern
interact
activ
apc
promot
antigenspecif
lymphocyt
respons
definit
pamp
broaden
recogn
structur
need
pathogen
thu
concept
microbeassoci
molecular
pattern
mamp
dangerdamageassoci
molecular
pattern
damp
defin
base
notion
endogen
host
molecul
signal
danger
damag
immun
system
tlr
singletransmembran
prr
local
cell
surfac
endosom
membran
prr
studi
tlr
play
crucial
role
innat
immun
respons
non
self
biosensor
tissu
damag
interact
four
known
tlr
adapt
tirapm
tram
trif
tlr
signal
shape
innat
immun
respons
besid
prr
innat
immun
system
also
detect
proteolyt
enzym
gener
infect
merg
respons
differ
prr
signal
may
pathway
develop
custom
respons
differ
aggress
b
experiment
model
adjuv
mani
anim
use
experiment
model
adjuvantrel
autoimmun
condit
includ
primat
salmon
rabbit
swine
howev
common
murin
model
murin
model
includ
autoimmun
prone
strain
model
autoimmun
diseas
autoimmun
resist
strain
tabl
interest
model
describ
lujan
et
al
author
describ
commerci
sheep
inocul
repetit
aluminumcontain
adjuv
vaccin
develop
acut
neurolog
episod
low
respons
extern
stimuli
acut
meningoenceph
day
immun
excitatori
phase
follow
weak
extrem
cachexia
tetraplegia
death
appear
suggest
part
spectrum
asia
syndrom
moreov
biopsi
nervou
tissu
experiment
anim
indic
presenc
alum
c
toxic
aluminum
adjuv
aluminum
nanoparticl
uniqu
capac
surpass
blood
brain
barrier
bbb
elicit
immun
inflammatori
respons
probabl
reason
aluminum
sensit
target
brain
also
document
side
effect
mostli
neurolog
neuropsychiatr
aluminum
present
natur
vaccin
adjuv
also
food
water
cosmet
describ
neurotoxin
even
rel
small
amount
aluminium
reach
brain
act
genotoxin
prooxid
proinflammatori
act
immunotoxin
also
endocrin
disruptor
aluminum
interfer
mani
essenti
cellular
process
memori
concentr
speech
deficit
impair
psychomotor
control
reduc
seizur
toler
alter
behaviour
manifest
aluminium
neurotox
moreov
alzheim
amyotroph
later
sclerosi
parkinson
dementia
multipl
sclerosi
neurolog
impair
children
link
aluminum
neurotox
brain
suscept
aluminum
compound
possibl
due
brain
high
metabol
requir
fact
possess
larg
area
biolog
membran
rel
low
concentr
antioxid
aluminum
adjuv
exert
immunostimulatori
effect
mani
differ
pathway
activ
innat
adapt
immun
system
one
signific
activ
inflammasom
pathway
activ
shown
trigger
type
diabet
use
knockout
mice
demonstr
absenc
inflammasom
compon
lead
better
mainten
glucos
homeostasi
higher
insulin
sensit
hand
activ
inflammasom
downstream
compon
proinflammatori
cytokin
strongli
implic
develop
sever
central
nervou
system
cn
disord
vast
major
peopl
consum
higher
amount
aluminum
dietari
parenter
intak
expert
author
consid
safe
upper
limit
set
us
food
drug
administr
fda
aluminum
vaccin
set
gdose
valu
base
toxic
studi
minimum
amount
need
aluminum
exert
effect
adjuv
quantiti
aluminum
infant
first
year
age
expos
consid
safe
fda
howev
scientif
basi
recommend
take
account
aluminum
persist
bodi
concern
aluminum
dietari
intak
reinforc
food
agricultur
fao
expert
committe
lower
provision
toler
weekli
intak
aluminum
mgkgbw
mgweek
averag
kg
human
mgkgbw
mgweek
amount
dietari
intak
aluminum
risen
urban
societi
mgday
consid
widespread
use
process
conveni
food
howev
dietari
aluminum
absorb
system
circul
thereaft
elimin
kidney
absorpt
aluminum
skin
ointment
cosmet
contain
aluminum
shown
moreov
presenc
aluminum
breast
tissu
associ
breast
cancer
aluminum
compound
persist
year
post
vaccin
human
bodi
fact
combin
repeat
exposur
may
account
hyper
activ
immun
system
subsequ
chronic
inflamm
clinic
experiment
evid
collect
far
identifi
least
three
main
risk
associ
aluminum
vaccin
persist
bodi
trigger
patholog
immunolog
respons
pass
bbb
cn
trigger
immunoinflammatori
process
result
brain
inflamm
longterm
neural
dysfunct
link
allergi
autoimmun
sinc
result
abnorm
immun
respons
metal
mercuri
aluminum
nickel
gold
known
induc
immunotox
effect
human
immunolog
effect
metal
includ
immunomodul
allergi
autoimmun
may
act
either
immunosuppress
immun
adjuv
metal
bind
firmli
cell
protein
thu
abil
modifi
autolog
epitop
hapeten
tcell
recogn
protein
foreign
trigger
autoimmun
respons
hypersensit
caus
metal
may
refer
type
iv
delay
hypersensit
reaction
consid
delay
first
symptom
appear
h
exposur
mostli
tcell
mediat
gold
standard
diagnosi
delay
type
hypersensit
patch
test
mercurysensit
patient
even
mercuri
concentr
within
normal
rang
might
provok
neuroallerg
reaction
brain
identifi
metal
sensit
remov
sensit
metal
dental
amalgam
prove
success
show
symptom
improv
patient
previou
autoimmun
diseas
diseas
includ
fibromyalgia
autoimmun
thyroid
diseas
orofaci
granulomatosi
tabl
timelin
regard
field
vaccinolog
divid
two
gener
first
regard
administr
inactiv
pathogen
whole
live
attenu
form
eg
bacillu
calmett
guerin
bcg
plagu
pertussi
polio
rabi
small
pox
second
regard
vaccin
assembl
purifi
microbi
cell
compon
also
refer
subunit
vaccin
eg
polysaccharid
protein
antigen
latter
approach
obstacl
convent
vaccin
develop
method
noncultiv
vitro
pathogen
eg
hepat
c
papilloma
viru
type
mycobacterium
lepra
antigen
hypervari
eg
serogroup
b
meningococcu
gonococcu
malaria
opportunist
pathogen
eg
staphylococcu
aureu
rapid
evolv
pathogen
human
immunodefici
viru
hiv
vaccin
research
gain
new
perspect
genom
field
emerg
last
decad
bacteri
genom
sequenc
analyz
make
possibl
choos
best
candid
vaccin
antigen
use
concept
revers
vaccinolog
main
known
factor
influenc
observ
heterogen
immun
respons
induc
vaccin
gender
age
ethnic
comorbid
immun
system
genet
background
interact
genet
environment
compon
dictat
respons
vaccin
studi
vaccin
host
enabl
develop
custom
treatment
option
combin
genet
epidemiolog
genom
vaccin
design
denomin
vaccinom
import
genet
influenc
support
twin
sibl
studi
show
famili
aggreg
suggest
genom
crucial
interindividu
variat
vaccin
immun
respons
human
leukocyt
antigen
hla
nonhla
gene
marker
identifi
marker
immun
respons
vaccin
multipl
studi
shown
connect
hla
gene
polymorph
nonrespons
hbv
vaccin
hla
region
divid
three
sub
region
class
associ
induct
mainten
cellmedi
immun
respons
class
ii
associ
present
exogen
antigen
helper
cell
class
iii
immun
non
hla
relat
gene
locat
normal
human
tissu
least
antigen
although
new
recombin
haplotyp
may
occur
inherit
mostli
intact
progenitor
hla
allel
differ
associ
differ
respons
vaccin
either
hyper
hypo
respons
infer
similar
respons
may
associ
differ
safeti
relat
develop
autoimmun
reaction
vaccin
particularli
patient
genet
predisposit
enhanc
respons
vaccin
inocul
furthermor
patient
share
hla
instanc
sibl
diagnos
asia
follow
similar
environment
stimuli
autoantibodi
help
diagnos
certain
autoimmun
diseas
howev
also
found
healthi
individu
thu
autoimmun
diseas
diagnos
base
sole
antibodi
detect
inocul
vaccin
trigger
autoimmun
respons
result
develop
autoantibodi
mani
studi
carri
anim
healthi
subject
patient
autoimmun
diseas
understand
develop
clinic
signific
differ
elicit
product
autoantibodi
healthi
human
observ
adjuv
nonadjuv
influenza
vaccin
annual
influenza
vaccin
heavili
research
vaccin
along
hpv
pneumococc
vaccin
far
relationship
patient
previous
diagnos
autoimmun
diseas
autoantibodi
induct
hpv
vaccin
also
shown
adolesc
girl
system
lupu
erythematosu
sle
although
induct
autoantibodi
proven
follow
vaccin
administr
proven
relat
diseas
diagnosi
either
specif
group
studi
far
wide
demonstr
autoantibodi
develop
year
manifest
fullblown
autoimmun
diseas
moreov
develop
specif
autoantibodi
also
genet
determin
link
genet
autoantibodi
vaccin
may
becom
even
intrigu
area
research
silicon
synthet
polym
use
fluid
emuls
resin
elastom
make
use
divers
field
thought
biolog
inert
substanc
incorpor
multitud
medic
devic
joint
implant
artifici
heart
valv
cathet
drain
shunt
siliconecontain
product
famou
like
breast
implant
silicon
one
substanc
suspect
induc
asia
current
believ
exposur
alon
enough
trigger
diseas
requir
presenc
addit
risk
factor
eg
genet
suscept
environment
factor
silicon
exert
local
tissu
reaction
reaction
consid
paraphysiolog
capsular
tissu
format
around
implant
reaction
view
abnorm
like
capsular
contractur
allerg
reaction
silicon
platinum
catalyst
use
silicon
polymer
found
minut
concentr
implant
occur
cutan
exposur
silicon
cosmet
babi
bottl
could
potenti
sensit
patient
also
system
compon
silicon
exposur
relat
diffus
silicon
elastom
envelop
commonli
term
bleed
may
arous
system
effect
degrad
fragment
tissu
also
spread
throughout
bodi
lead
develop
cancer
autoimmun
phenomena
patient
ruptur
implant
complain
frequent
pain
chronic
fatigu
compar
patient
intact
implant
antisilicon
antibodi
found
present
human
sera
frequent
patient
undergon
silicon
breast
implant
howev
patholog
signific
remain
uncertain
seen
antibodi
autoantibodi
direct
dsdna
ssdna
ssbla
silicon
collagen
ii
found
present
increas
level
patient
exposur
silicon
also
shown
format
autoantibodi
directli
relat
implant
durat
sever
autoimmun
diseas
link
silicon
exposur
includ
rheumatoid
arthriti
ra
system
lupu
erythematosu
sle
polymyos
system
sclerosi
ssc
fibromyalgia
although
asia
symptom
may
aris
year
onset
exposur
silicon
implant
followup
period
short
conclud
evid
yet
come
regard
causal
publish
case
report
epidemiolog
research
studi
suggest
connect
sever
vaccin
certain
autoimmun
condit
notwithstand
overal
benefit
vaccin
outweigh
risk
thrombocytopenia
report
main
advers
event
follow
mmr
vaccin
mmr
vaccin
onset
immun
thrombocytopen
purpura
itp
usual
occur
within
week
risk
rate
mmr
vaccin
dose
incid
itp
follow
infect
measl
rubella
risk
thrombocytopenia
higher
patient
experi
natur
infect
measl
mump
rubella
receiv
vaccin
vaccin
encourag
arthralgia
complaint
also
report
may
present
transient
arthralgia
acut
arthriti
rare
chronic
arthriti
risk
factor
found
associ
develop
arthriti
vaccin
patient
femal
gender
older
age
prior
seroneg
specif
hla
allel
yf
vaccin
advis
peopl
go
endem
area
risk
develop
yf
vaccineassoci
neurolog
diseas
yeland
invers
proport
age
children
age
month
vaccin
month
except
epidem
vaccin
advis
peopl
year
possibl
higher
risk
sever
advers
effect
sae
even
though
incid
remain
low
besid
vaccin
mycobacterium
tuberculosi
tb
bcg
prove
effect
immunotherapi
bladder
cancer
although
mechan
yet
fulli
understood
thought
bcg
bind
fibronectin
form
complex
enabl
recognit
nonself
innat
immun
respons
cell
ultim
pathway
result
apoptosi
tumor
cell
effect
treat
nonmuscleinvas
urotheli
carcinoma
well
superfici
bladder
tumor
expect
bcg
could
play
role
treat
type
cancer
despit
data
corrobor
hypothesi
far
advers
event
vari
accord
site
method
administr
intraderm
administr
bcg
report
elicit
arthriti
dermatomyos
takayasu
arter
ta
among
other
intraves
treatment
bladder
cancer
caus
reactiv
arthriti
rea
risk
reli
system
reaction
compos
earli
infect
phase
pcr
posit
respons
antitb
treatment
late
hypersensit
reaction
hbv
dna
viru
hepadnavirida
famili
respons
acut
chronic
liver
diseas
hbv
vaccin
consid
first
effici
vaccin
major
human
cancer
hbv
vaccin
reduc
risk
develop
chronic
infect
also
prove
reduc
incid
liver
cancer
children
vaccin
associ
mainli
autoimmun
neuromuscular
disord
includ
limit
optic
neuriti
guillainbarr
syndrom
gb
myeliti
multipl
sclerosi
ms
system
lupu
erythematosu
sle
arthriti
vascul
antiphospholipid
syndrom
ap
myopathi
hbv
vaccin
common
immun
associ
acut
myeliti
studi
indic
pathogen
behind
vaccin
autoimmun
might
base
crossreact
hbv
antigen
hbsag
epitop
yeast
antigen
well
adjuv
contain
vaccin
cervic
cancer
death
occur
develop
countri
lack
abil
fulli
implement
papanicolau
pap
screen
program
hpv
pose
special
challeng
vaccin
safeti
hpv
necessari
develop
cervic
cancer
howev
women
infect
hpv
develop
diseas
sinc
infect
resolv
within
year
within
year
without
specif
treatment
cours
decad
cancer
may
result
small
proport
remain
infect
women
death
rate
cervic
cancer
year
old
girl
zero
longterm
benefit
yet
proven
specif
case
short
term
risk
healthi
subject
prove
pose
heavier
burden
cervic
cancer
least
type
hpv
strain
patholog
associ
cancer
two
vaccin
gardasil
tm
cervarix
tm
commerci
avail
hpv
contain
capsid
protein
sever
hpv
strain
antigen
gardasil
tm
contain
serotyp
antigen
combin
aluminum
al
hydroxyphosph
sulphat
adjuv
cervarix
tm
contain
combin
oilbas
adjuv
monophosphoryl
lipid
mpl
al
hydroxid
adjuv
direct
strain
sever
report
postlicensur
advers
event
even
fatal
compar
vaccin
unusu
high
proport
advers
drug
reaction
report
associ
hpv
vaccin
australia
report
annual
adr
rate
highest
sinc
increas
almost
entir
due
adr
report
follow
commenc
nation
hpv
vaccin
program
femal
age
year
april
total
adr
record
number
decreas
cessat
catchup
schedul
although
percentag
convuls
attribut
hpv
vaccin
decreas
overal
report
remain
compar
respect
report
prove
associ
show
higher
frequenc
adr
relat
hpv
vaccin
report
worldwid
fit
consist
pattern
ie
nervou
systemrel
disord
rank
highest
frequenc
deserv
investig
inde
sever
autoimmun
diseas
link
hpv
immun
exampl
includ
gb
ms
acut
dissemin
encephalomyel
adem
transvers
myeliti
tm
postur
orthostat
tachycardia
syndrom
pot
sle
primari
ovarian
failur
pof
pancreat
vascul
immun
thrombocytopen
purpura
itp
autoimmun
hepat
ah
influenza
acut
viral
infect
affect
respiratori
tract
caus
influenza
type
ac
virus
orthomyxovirida
famili
mortal
rate
outbreak
show
high
risk
age
year
older
presenc
chronic
diseas
delay
admiss
risk
infect
lower
vaccin
season
influenza
trival
inactiv
vaccin
studi
demonstr
influenza
vaccin
safe
immunogen
patient
sle
rheumatoid
arthriti
ra
diminish
risk
respiratori
infect
shown
adjuv
vaccin
local
reaction
increas
system
advers
reaction
molecular
mimicri
suggest
mechan
explain
autoimmun
respons
follow
influenza
vaccin
howev
causal
relationship
influenza
vaccin
induct
autoimmun
diseas
remain
unprov
diseas
symptom
report
influenza
vaccin
includ
mostli
neurolog
syndrom
gb
ref
nonetheless
influenza
vaccin
recommend
patient
ms
influenza
infect
associ
increas
risk
exacerb
said
influenza
vaccin
show
increas
risk
autoimmun
respons
suggest
asia
vascul
ap
among
other
meningococc
diseas
caus
neisseria
meningitidi
one
follow
five
serogroup
caus
almost
everi
invas
diseas
ac
vaccin
avail
far
prevent
encompass
either
pure
polysaccharid
vaccin
use
purifi
bacteri
capsular
polysaccharid
antigen
proteinpolysaccharid
conjug
vaccin
use
polysaccharid
molecul
plu
diphtheria
tetanu
toxoid
tcellstimul
antigen
n
meningitidi
serogroup
b
menb
menb
glycoconjug
vaccin
immunogen
henc
vaccin
design
focus
subcapsular
antigen
menb
capsular
polysaccharid
compos
linear
homopolym
nacetylneuroamin
acid
polysial
acid
psa
menb
psa
psa
found
neural
cell
adhes
molecul
structur
ident
result
propos
infect
menb
vaccin
psa
may
associ
subsequ
autoimmun
neurolog
diseas
evid
increas
autoimmun
found
associ
meningococc
serogroup
b
infect
regard
vaccin
inocul
caus
autoimmun
diseas
may
unmask
autoimmun
phenomena
genet
predispos
individu
local
reaction
frequent
individu
vaccin
quadrival
meningococc
conjug
vaccin
compar
plain
polysaccharid
vaccin
intramuscular
administr
conjug
vaccin
versu
subcutan
polysaccharid
may
part
explain
higher
reactiv
diseas
previous
associ
meningococc
vaccin
gb
purpura
hsp
bullou
pemphigoid
bp
streptococcu
pneumonia
pneumococcu
main
caus
bacteri
communityacquir
pneumonia
mening
western
countri
well
caus
children
death
develop
countri
three
antipneumococc
vaccin
commerci
avail
two
conjug
protein
carrier
one
conjug
licens
consist
capsular
polysaccharid
twentythre
differ
streptococcu
pneumonia
serotyp
v
elicit
immunolog
memori
immun
respons
trigger
tcell
independ
usual
administ
elderli
year
believ
less
effect
children
compos
frequent
serotyp
v
direct
serotyp
v
contrari
aluminum
adjuv
composit
elicit
tcell
mediat
respons
ever
sinc
vaccin
introduc
healthcar
system
preval
fatal
admiss
invas
pneumococc
diseas
decreas
significantli
vaccin
advers
event
vari
depend
whether
vaccin
adjuv
non
adjuv
vaccin
local
reaction
present
peopl
vaccin
intra
muscularli
immun
subcutan
conjug
vaccin
percentag
rise
system
reaction
fever
irrit
decreas
appetit
sleep
disturb
occur
recipi
pcv
ppv
symptom
like
arthralgia
arthriti
myalgia
paresthesia
fatigu
frequent
patient
post
ppv
may
relat
fact
vaccin
administ
differ
age
group
autoimmun
risk
follow
ppv
vaccin
low
case
report
found
ppv
vaccin
six
refer
reactiv
previou
autoimmun
disord
studi
direct
access
vaccin
safeti
subject
autoimmun
diseas
show
immun
safe
tetanu
toxoid
tt
potent
exotoxin
produc
bacteria
clostridium
tetani
toxin
predomin
effect
inhibitori
neuron
inhibit
releas
acid
gaba
spinal
inhibitori
interneuron
affect
symptom
appear
vaccin
c
tetani
contain
deactiv
tetanu
toxoid
plu
adjuv
usual
aluminium
hydroxid
studi
preval
diseas
associ
tt
antiphospholipid
syndrom
ap
cn
complic
also
report
optic
neuriti
acut
myeliti
encephalomyel
mice
immun
respons
tt
depend
genet
background
specif
adjuv
use
immun
naiv
balbc
mice
immun
tt
develop
antibodi
direct
tt
dsdna
extrem
sick
ap
autoimmun
diseas
character
occurr
thrombot
event
patient
suffer
condit
recurr
fetal
loss
thromboembol
phenomena
thrombocytopenia
well
neurolog
cardiac
dermatolog
involv
serolog
marker
ap
presenc
antiphospholipid
antibodi
apl
bind
neg
charg
phospholipid
platelet
endotheli
cell
mainli
plasma
protein
presenc
igg
igm
anticardiolipin
antibodi
acl
lupu
anticoagul
associ
thrombosi
patient
ap
identifi
import
antigen
ap
sever
properti
vitro
defin
anticoagul
eg
inhibit
prothrombinas
activ
adenosin
diphosphateinduc
platelet
aggreg
platelet
factor
ix
product
passiv
transfer
antibodi
induc
experiment
ap
mice
thrombu
format
ex
vivo
model
evid
suggest
molecular
mimicri
mechan
tt
one
possibl
caus
ap
besid
tt
ap
also
report
follow
hbv
influenza
viru
vaccin
although
data
scarc
sle
multisystem
autoimmun
diseas
character
product
varieti
autoantibodi
igg
isotyp
antibodi
doublestrand
dna
dsdna
thought
diagnost
marker
presenc
correl
diseas
pathogenesi
sever
factor
includ
genet
hormon
environment
immun
defect
involv
induct
autoantibodi
diseas
post
vaccin
manifest
sle
lupu
like
syndrom
report
rang
autoantibodi
induct
full
blown
clinic
diseas
report
publish
associ
sle
hbv
mmr
dtp
hpv
influenza
bcg
pneumococc
small
pox
vaccin
vaccin
sle
diagnos
patient
associ
diseas
exacerb
decreas
antibodi
respons
may
due
underli
diseas
frequent
use
immunosuppress
drug
tempor
link
sle
hbv
vaccin
relat
demonstr
sever
studi
demonstr
increas
preval
hpv
individu
lupu
compar
gener
popul
increas
awar
need
vaccin
highrisk
popul
associ
immun
hpv
vaccin
sle
like
symptom
well
higher
incid
flare
known
lupu
patient
must
taken
account
vascul
name
given
group
autoimmun
mediat
diseas
involv
blood
vessel
differ
type
size
categor
accord
sever
diseas
featur
indlud
type
vessel
affect
organ
distribut
genet
predisposit
clinic
manifest
far
case
larg
vessel
vascul
detect
includ
case
giant
cell
arter
gca
follow
influenza
vaccin
case
takayasu
diseas
td
one
case
larg
cell
arter
involv
subclavian
renal
arteri
follow
hbv
vaccin
two
patient
previou
receiv
diagnosi
ankylos
spondyl
polymyalgia
rheumatica
pmr
like
ill
one
case
polyarter
nodosa
pan
follow
administr
tetanu
bcg
vaccin
describ
case
pan
adult
follow
administr
hbv
vaccin
case
report
medium
vessel
vascul
polyarter
nodosa
kawasaki
diseas
kd
also
publish
pediatr
patient
kd
describ
one
day
second
dose
hbv
vaccin
follow
yellow
fever
vaccin
two
case
pediatr
patient
pan
report
two
month
receiv
hbv
vaccin
eosinophil
granulomatosi
polyangi
egpa
tetanu
vaccin
follow
hbv
vaccin
report
also
case
microscop
polyangi
mpa
case
granulomatosi
polyangi
gpa
follow
influenza
vaccin
literatur
henoch
purpura
hsp
common
vascul
childhood
gener
benign
selflimit
mediat
iga
immun
complex
deposit
variou
tissu
well
smallsiz
blood
vessel
genet
risk
factor
play
import
role
pathogenesi
diseas
associ
hladrb
hsp
associ
season
influenza
influenza
pneumococc
meningococc
diseas
hepat
viru
hav
hbv
antihuman
papilloma
viru
hpv
vaccin
follow
multipl
combin
vaccin
typhoid
cholera
yellow
fever
leukocytoclast
vascul
associ
sever
vaccin
includ
influenza
vaccin
hav
vaccin
hbv
vaccin
pneumococc
vaccin
varicella
rubella
smallpox
anthrax
vaccin
dermal
vascul
pan
uveiti
also
describ
follow
mmr
vaccin
ra
preval
chronic
inflammatori
arthriti
affect
synovi
membran
multipl
diarthrodi
joint
although
etiolog
complet
clarifi
deregul
immun
system
evid
preponder
inflammatori
cytokin
immun
cell
within
joint
ra
estim
herit
leav
substanti
proport
risk
environment
factor
immun
previous
propos
potenti
environment
trigger
ra
norfolk
arthriti
regist
databas
first
patient
report
receiv
tetanu
vaccin
within
week
prior
onset
arthriti
similarli
transient
rise
rf
titer
record
militari
recruit
week
receiv
concomit
immun
tetanu
typhoid
paratyphoid
mump
diphtheria
polio
smallpox
howev
show
persist
elev
titer
none
develop
arthriti
sever
mechan
propos
explain
put
associ
vaccin
initi
ra
promin
molecular
mimicri
nonspecif
immun
system
activ
vaccin
associ
ra
includ
rubella
vaccin
reactiv
arthriti
occur
recipi
control
studi
fail
show
persist
arthriti
arthralgia
patient
patient
follow
hbv
vaccin
show
increas
arthriti
vaer
studi
seen
larg
retrospect
epidemiolog
studi
data
far
suggest
vaccin
carri
insignific
role
pathogenesi
ra
sever
mechan
studi
produc
vaccin
mainli
target
inflammatori
cytokin
antigen
tnf
aim
induc
high
titer
endogen
neutral
anticytokin
antibodi
goal
break
natur
th
toler
auto
antigen
cytokin
name
mif
rant
also
test
anoth
vaccin
relat
therapi
use
autolog
cell
line
induc
specif
immun
respons
host
cell
direct
autoimmun
vaccin
cell
strategi
success
mous
model
shown
encourag
result
small
pilot
studi
ra
patient
patient
show
clinic
respons
defin
acr
improv
criteria
uctd
clinic
condit
character
sign
symptom
laboratori
test
suggest
system
autoimmun
diseas
fulfil
criteria
defin
connect
tissu
diseas
ctd
patient
clinic
manifest
suggest
system
connect
tissu
diseas
fulfil
exist
criteria
quit
frequent
patient
initi
ask
rheumatolog
evalu
may
least
temporarili
diagnos
affect
undefin
undifferenti
connect
tissu
diseas
compar
studi
diseas
unfeas
inexist
defin
criteria
diagnosi
within
year
followup
patient
usual
evolv
defin
ctd
includ
sle
system
sclerosi
ssc
primari
syndrom
pss
mix
connect
tissu
diseas
mctd
system
vascul
polydermatomyos
pmdm
ra
maintain
undefin
profil
year
make
evolv
ctd
less
probabl
diagnosi
stabl
uctd
reliabl
diseas
etiolog
concern
associ
vitamin
defici
silicon
implant
lead
imbal
proinflammatori
antiinflammatori
cytokin
vaccin
also
associ
diseas
name
hbv
vaccin
etiopathogenesi
uctd
unknown
suggest
might
fall
asia
spectrum
sinc
symptomat
similar
strike
uctd
etiopathogenesi
associ
adjuv
aa
autoimmun
diseas
character
one
well
demarc
oval
round
noncicatrici
patch
hair
loss
diseas
may
affect
hair
bear
part
bodi
great
impact
patient
selfesteem
qualiti
life
depend
ethnic
locat
aa
preval
skin
diseas
aa
preval
vari
estim
unit
state
singapor
autoimmun
diseas
develop
aa
encompass
genet
environment
factor
environment
factor
associ
aa
develop
emot
andor
physic
stress
infect
vaccin
secondari
syphili
one
well
studi
exampl
howev
epstein
barr
viru
herp
zoster
infect
also
relat
develop
diseas
far
vaccin
go
hbv
vaccin
associ
aa
develop
one
studi
patient
develop
aa
vaccin
hbv
vaccin
patient
rechalleng
reappear
diseas
wit
mice
associ
fail
establish
one
case
aa
wit
follow
tetanu
toxoid
well
two
case
report
follow
hpv
mmr
vaccin
itp
autoimmun
diseas
defin
platelet
count
less
plateletsl
without
overlap
diseas
present
without
antiplateletantibodi
thrombocytopenia
rel
common
overal
probabl
develop
itp
cohort
patient
also
found
patient
develop
overlap
aid
itp
etiolog
diseas
yet
fulli
understood
detect
follow
infecti
diseas
helicobact
pylori
hepat
c
viru
hcv
novel
influenza
infect
rotaviru
infect
human
immunodefici
viru
hiv
itp
onset
also
report
although
rare
sever
advers
event
follow
vaccin
administr
often
observ
measlesmumpsrubella
mmr
hepat
b
diphtheriatetanusacellular
pertussi
dtap
varicella
vaccin
molecular
mimicri
suggest
possibl
mechan
develop
itp
name
follow
helicobact
pylori
infect
erad
shown
increas
platelet
count
diminish
level
anticaga
antibodi
subset
h
pylori
infect
subject
itp
data
point
toward
benefici
role
h
pylori
erad
chronic
itp
two
case
itp
follow
antirabi
vaccin
report
one
hpv
vaccin
reactiv
itp
report
two
week
tickborn
enceph
vaccin
consist
associ
itp
mmr
vaccin
howev
emphas
number
case
fewer
expect
without
vaccin
due
antigen
specif
reaction
insulin
produc
beta
cell
pancrea
much
like
autoimmun
diseas
result
combin
genet
environment
hormon
immunolog
factor
environment
factor
pathogen
diet
toxin
stress
vaccin
believ
involv
begin
autoimmun
process
although
mechan
viral
infect
caus
autoimmun
diabet
fulli
clarifi
evid
suggest
role
natur
infect
pathogenesi
mellitu
suscept
individu
hypothes
vaccin
could
trigger
suscept
individu
although
postvaccin
may
biolog
plausibl
cumul
evid
support
increas
risk
follow
vaccin
sever
experiment
data
suggest
depend
time
vaccin
might
exert
protect
aggrav
effect
occurr
diabet
studi
suggest
haemophillu
influenza
type
b
vaccin
might
risk
factor
induct
islet
cell
antigad
antibodi
measur
one
year
age
previou
studi
show
associ
hib
cohort
american
militari
offic
diagnos
associ
found
vaccin
diagnosi
avail
data
relat
mump
vaccin
still
incomplet
interpret
difficult
miscellan
confound
factor
associ
develop
associ
hemagglutinin
neuraminidas
vaccin
far
unproven
human
hypothes
earlyag
bcg
vaccin
associ
risk
studi
conduct
date
provid
consist
evid
associ
howev
studi
show
possibl
temporari
boost
immun
function
vaccin
studi
also
show
among
bcgvaccin
children
test
posit
islet
autoantibodi
higher
cumul
risk
anim
experi
observ
bcg
seem
protect
effect
diabet
howev
research
yet
translat
benefit
human
studi
result
support
strong
associ
vaccin
narcolepsi
sleep
disord
describ
excess
sleepi
abnorm
sleep
pattern
character
uncontrol
rapid
eye
movement
rem
event
occur
time
day
event
may
may
accompani
loss
muscl
tone
cataplexi
plethora
data
indic
narcolepsi
caus
lack
orexin
also
known
hypocretin
import
neurotransmitt
involv
regul
sleep
cycl
narcolepsi
patient
loss
orexin
produc
neuron
hypothalamu
low
level
orexin
cerebrospin
fluid
csf
report
narcolepsi
shown
autoimmun
background
antibodi
tribbl
found
patient
may
relat
pathogenesi
diseas
experiment
model
narcolepsi
mice
made
passiv
transfer
total
igg
narcolepsi
patient
anim
brain
intra
ventricular
inject
environment
factor
like
influenza
viru
streptococc
infect
associ
diseas
onset
interestingli
fever
without
diagnosi
infecti
etiolog
found
risk
factor
narcolepsi
sever
group
studi
found
increas
incid
narcolepsi
diagnosi
follow
introduct
influenza
vaccin
specif
pandemrix
tm
vaccin
associ
shown
finland
especi
yearold
also
case
report
countri
studi
fail
find
associ
actual
infect
associ
diseas
develop
china
howev
relationship
note
europ
abovement
associ
specif
relat
pandemrix
tm
vaccin
associ
report
adjuv
nonadjuv
vaccin
major
differ
adjuv
presenc
uniqu
achiev
highest
longest
antibodi
respons
produc
enhanc
antigenspecif
adapt
immun
respons
vitro
shown
could
increas
product
orexin
well
increas
proteosom
activ
increas
product
orexin
fragment
may
facilit
antigen
present
mhc
class
ii
thu
trigger
autoimmun
process
data
togeth
support
relationship
pandemrix
tm
vaccin
develop
narcolepsi
gluten
induc
enteropathi
gluten
sensit
enteropathi
commonli
call
celiac
diseas
cd
lifelong
autoimmun
condit
mainli
gastrointestin
tract
specif
affect
small
intestin
abnorm
immun
respons
crate
autoantigen
direct
toward
tissu
transglutaminas
ttg
two
main
autoantibodi
widespread
serolog
marker
screen
diseas
anti
ttg
anti
endomysium
two
addit
autoantibodi
name
anti
deamin
gliadin
peptid
antineoepitop
ttg
found
recent
reliabl
cd
screen
well
cd
autoimmun
diseas
induc
wellknown
nutrit
environment
factor
nondietari
one
less
studi
establish
sever
infecti
diseas
link
develop
socal
infectom
clear
causeeffect
relat
yet
establish
pathogen
associ
cd
shown
howev
countri
low
econom
statu
inferior
hygien
condit
higher
infecti
load
cd
preval
lower
epidemiolog
relationship
establish
rotaviru
infect
cd
data
show
genet
predispos
individu
rotaviru
infect
relat
childhood
cd
develop
subsequ
research
studi
celiac
peptid
recogn
prove
share
homolog
rotaviru
major
neutral
protein
cd
autoantigen
ttg
antibodi
direct
viral
protein
shown
predict
onset
cd
induc
typic
featur
cd
intestin
epitheli
celllin
also
suggest
rotaviru
vaccin
alter
b
behavior
percentag
bcell
higher
vaccin
infant
rotaviru
vaccin
induc
cd
still
discuss
warrant
studi
pmr
autoimmun
inflammatori
rheumat
diseas
character
rais
inflammatori
marker
pain
morn
stiff
shoulder
pelvic
girdl
synov
proxim
joint
extraarticular
synovi
structur
diagnosi
clinic
typic
diseas
elderli
occur
mainli
subject
etiopathogenesi
pmr
remain
unknown
genet
environment
factor
play
role
close
tempor
relationship
ascertain
concern
epidem
mycoplasma
pneumonia
chlamydia
pneumonia
parvoviru
peak
case
pmr
giant
cell
arter
howev
clearli
proven
case
pmr
follow
vaccin
rare
report
howev
believ
post
vaccin
pmr
may
underreport
due
symptomat
similar
transient
effect
vaccin
name
arthralgia
myalgia
lowgrad
fever
lead
failur
establish
chronolog
relationship
diseas
diagnos
report
case
associ
season
influenza
vaccin
infv
often
time
interv
vaccin
administr
symptom
onset
vari
one
day
three
month
three
case
report
associ
giant
cell
arthriti
case
report
relaps
pmr
four
year
remiss
follow
tetanu
vaccin
also
report
acut
dissemin
encephalomyel
adem
inflammatori
demyelin
diseas
central
nervou
system
cn
adem
usual
polysymptomat
encephalopathi
ie
behavior
chang
alter
level
conscious
affect
mostli
children
young
adult
higher
preval
male
incid
per
per
year
although
concret
evid
clear
pathogen
associ
adem
associ
immun
previou
viral
infect
postvaccin
adem
account
percent
case
postinfecti
adem
account
percent
case
adem
hypothesi
better
describ
associ
molecular
mimicri
tcell
target
human
coronaviru
influenza
viru
epsteinbarr
viru
ebv
shown
crossreact
myelin
basic
protein
mbp
antigen
antimbp
tcell
detect
patient
follow
vaccin
simpl
rabi
vaccin
post
experiment
therapi
alzheim
diseas
vaccin
contain
aggreg
synthet
fragment
amyloid
precursor
protein
adem
shown
develop
mice
experiment
model
ms
eae
mice
may
induc
inject
latter
administ
togeth
complet
freund
adjuv
observ
point
import
central
role
adjuv
induct
adem
autoimmun
gener
overal
incid
post
vaccin
adem
estim
per
higher
risk
report
follow
immun
measl
vaccin
account
postvaccin
adem
includ
vaccin
varicella
zoster
rubella
smallpox
influenza
virus
surprisingli
certain
vaccin
antitetanu
vaccin
shown
neg
correl
adem
statist
signific
decreas
risk
hbv
immun
studi
possibl
caus
adem
later
associ
clinic
isol
syndrom
ci
first
time
occur
demyelin
episod
may
develop
ms
complet
convers
ms
far
case
report
concern
adem
associ
vaccin
influenza
hepat
b
mmr
hpv
tetanu
bullou
dermatos
character
presenc
blister
autoantibodi
structur
compon
skin
desmosom
protein
pemphigu
adhes
molecul
dermalepiderm
junction
pemphigoid
diseas
epiderm
tissu
transglutaminas
dermat
herpetiformi
frequent
autoimmun
bullou
diseas
bullou
pemphigoid
bp
pemphigu
vulgari
pv
bp
frequent
observ
elderli
age
onset
pv
year
neither
diseas
gender
prefer
bp
pv
etiolog
far
poorli
understood
diseas
associ
variou
environment
factor
includ
emot
andor
physic
stress
infect
vaccin
genet
predisposit
also
studi
overexpress
certain
hla
class
ii
allel
includ
allel
found
preval
bp
patient
gener
popul
pv
associ
certain
hla
class
ii
loci
allel
preval
ashkenazi
jew
iranian
sardinian
patient
loci
includ
common
among
japanes
italian
patient
two
allel
strongli
associ
pv
bp
pv
patient
sera
found
significantli
higher
preval
antibodi
hepat
b
viru
hepat
c
viru
helicobact
pylori
toxoplasma
gondii
cytomegaloviru
far
vaccin
concern
bp
develop
patient
follow
influenza
diphtheria
tetanu
pertussi
hepat
b
bcg
polio
herp
zoster
vaccin
furthermor
reactiv
bp
follow
influenza
vaccin
report
one
case
report
new
onset
pv
associ
influenza
vaccin
hepat
b
vaccin
anthrax
vaccin
typhoid
booster
rabi
vaccin
addit
exacerb
pv
vaccin
also
report
follow
influenza
vaccin
tetanu
vaccin
iim
compos
group
skelet
muscl
diseas
myositi
without
recogn
caus
occur
iim
usual
subdivid
entiti
dermatomyos
dm
polymyos
pm
inclus
bodi
myositi
sibm
nonspecif
myositi
nsm
immun
mediat
necrot
myopathi
iam
iim
preval
around
case
bimod
age
distribut
peak
childhood
year
dm
common
inflammatori
myopathi
pm
least
frequent
despit
exhibit
similar
clinic
symptom
subset
iim
exhibit
signific
immunopatholog
variat
dm
begin
activ
complement
format
membran
attack
complex
mac
pm
sibm
fundament
process
relat
cell
mediat
cytotox
unclear
break
toler
drive
immun
respons
induc
iim
far
dm
pm
sibm
link
vaccin
sever
case
report
literatur
associ
differ
vaccin
develop
idiopath
inflammatori
myopathi
case
iim
report
vaer
databas
june
case
classifi
pm
dm
one
sibm
dm
report
almost
vaccin
howev
studi
attempt
clarifi
possibl
relationship
dm
vaccin
pm
frequent
misdiagnos
disord
report
associ
previou
immun
especi
hepat
b
vaccin
pm
despit
recent
differenti
iim
sibm
alreadi
relat
hbv
vaccin
vaccin
associ
myositi
mmr
vaccin
smallpox
vaccin
poliomyel
ipv
diphtheria
tetanu
toxoid
influenza
hpv
bcg
fm
entiti
relat
inabl
cn
modul
pain
condit
pain
modul
process
cn
appear
compromis
among
mani
fm
patient
might
explain
enhanc
pain
sensat
experienc
patient
etiolog
fm
yet
unveil
genet
predisposit
physic
trauma
particularli
cervic
spine
emot
stress
variou
stressor
well
varieti
infect
link
fm
vaccin
associ
trigger
fm
name
rubella
lyme
diseas
vaccin
sever
report
fibromyalgialik
diseas
vaccin
specif
hpv
martinezlavin
journal
clinic
rheumatolog
medic
commun
regulatori
agenc
awar
possibl
advers
effect
aim
defin
magnitud
chronic
fatigu
syndrom
cf
diseas
character
disabl
fatigu
headach
concentr
difficulti
memori
deficit
symptom
sore
throat
tender
lymph
node
skelet
muscl
pain
feverish
sleep
disrupt
psychiatr
problem
rapid
puls
often
observ
frequent
affect
women
preval
although
diseas
etiolog
still
unknown
sever
pathogen
epsteinbarr
viru
ebv
associ
cf
patient
often
higher
titer
igm
ebv
viral
capsid
antigen
cytomegaloviru
human
herp
viru
antibodi
also
detect
often
cf
patient
although
report
fail
replic
result
parvoviru
infect
also
suggest
trigger
cf
vaccin
inocul
also
appoint
probabl
caus
vaccin
rubella
q
fever
hepat
b
found
associ
higher
risk
develop
cf
meningococc
vaccin
polioviru
influenza
vaccin
surprisingli
staphylococcu
toxoid
vaccin
appear
protect
effect
defin
shoenfeld
agmonlevin
asia
syndrom
character
hyperact
immun
respons
adjuv
previous
state
asia
incorpor
four
known
medic
condit
siliconosi
gw
mmf
postvaccin
phenomena
recent
sick
build
syndrom
sb
propos
candid
asia
spectrum
diseas
satisfi
sever
criteria
fm
seid
macrophag
myofasci
mmf
mmf
describ
emerg
condit
unknown
caus
character
pathognomon
lesion
muscl
biopsi
mix
larg
macrophag
submicron
microns
agglomer
nanocryst
cytoplasm
lymphocyt
infiltr
lesion
relat
aluminum
deposit
muscl
follow
immun
aluminum
contain
vaccin
mmf
lesion
univers
recogn
indic
longlast
persist
aluminum
adjuv
site
prior
intramuscular
immun
longlast
mmf
lesion
consid
biomark
aluminum
bio
persist
given
individu
patient
mmf
higher
report
myalgia
incid
etiolog
clear
genuin
muscl
weak
rare
diagnosi
fibromyalgia
also
rare
higher
preval
chronic
fatigu
syndrom
cf
patient
mmf
report
well
cognit
impair
associ
mmf
one
seri
mmf
patient
attent
memori
complaint
neuropsycholog
test
abnorm
b
gulf
war
syndrom
gw
gw
clinic
entiti
specif
relat
certain
time
place
histori
describ
among
veteran
militari
conflict
occur
persian
gulf
syndrom
character
chronic
fatigu
musculoskelet
symptom
malais
cognit
impair
clinic
overlap
post
traumat
stress
disord
ptsd
fm
cf
function
disord
uniqu
condit
associ
far
diseas
develop
exposur
extrem
climat
persian
gulf
exposur
variou
chemic
pesticid
deplet
uranium
stress
provok
prolong
wait
without
actual
combat
intens
exposur
vaccin
soldier
fear
biolog
weaponri
compar
gulf
war
veteran
veteran
bosnian
conflict
multipl
vaccin
administ
servicemen
gulf
war
identifi
uniqu
exposur
mechan
vaccin
exposur
may
lead
develop
function
symptom
complet
understood
possibl
shift
type
reaction
could
pathogen
signific
rais
support
increas
frequenc
allerg
reaction
low
natur
killer
cell
activ
low
level
interferon
patient
one
studi
gw
patient
show
connect
antisqualen
antibodi
symptom
develop
refut
larger
studi
found
associ
antisqualen
antibodi
chronic
multisymptom
ill
c
asia
registri
registri
collect
data
relat
patient
specif
characterist
often
first
approach
studi
area
inquiri
rare
diseas
registri
often
way
get
suffici
size
sampl
patient
use
either
epidemiolog
research
purpos
asia
syndrom
may
underreport
unawar
failur
connect
syndrom
exposur
registri
creat
fulli
understand
clinic
aspect
diseas
compar
patient
world
order
fulli
valid
criteria
diseas
diagnosi
also
defin
demograph
environment
histori
diseas
asia
syndrom
registri
websit
found
follow
link
http
ontocrfcostisacomenwebasia
case
report
physician
accept
make
inform
decis
medicin
alway
need
weigh
pro
con
ard
may
play
import
role
decid
whether
vaccin
appropri
patient
case
patient
immunosuppress
account
diagnosi
even
specif
immunomodelatori
medic
efficaci
vaccin
reduc
potenti
develop
diseas
flare
follow
vaccin
case
live
vaccin
inocul
may
even
enough
trigger
diseas
host
specif
reason
live
vaccin
gener
contraind
patient
receiv
immunosuppress
medic
need
screen
treatment
latent
tuberculosi
infect
ltbi
start
antitnfalpha
therapi
true
vaccin
prefer
even
recommend
vaccin
see
tabl
administ
initi
diseasemodifi
antirheumat
drug
dmard
may
reduc
vaccin
efficaci
immunosuppress
equal
high
risk
infect
lower
vaccin
efficaci
take
account
safeti
concern
efficaci
eular
recommend
immun
aiird
patient
assess
vaccin
statu
initi
investig
administ
vaccin
stabl
diseas
phase
live
attenu
vaccin
avoid
especi
immunosuppress
agent
administ
bcg
recommend
administ
vaccin
ideal
start
dmard
agent
influenza
polysaccharid
pneumococc
vaccin
recommend
tetanu
toxoid
vaccin
recommend
follow
recommend
gener
popul
case
major
andor
contamin
wound
patient
receiv
rituximab
previou
week
tetanu
ig
indic
hpv
herp
zoster
consid
hyposplenicasplen
patient
influenza
pneumococc
haemophilu
influenza
b
meningococc
c
advis
hepat
b
recommend
patient
risk
travel
patient
immun
accord
gener
popul
guidelin
except
live
attenu
vaccin
avoid
vaccin
mani
benefici
effect
combat
infecti
diseas
prevent
mortal
morbid
also
prove
effect
cancer
treatment
immunomodul
demonstr
intraves
administr
bcg
treat
superfici
bladder
cancer
vaccin
howev
link
autoimmun
benefici
outcom
like
adjuv
effect
base
immun
trigger
enhanc
immun
mechan
respons
account
autoimmun
exert
vaccin
induc
product
autoantibodi
patholog
effect
yet
unveil
although
vaccin
wide
consid
safe
subject
predisposit
vaccin
pose
bigger
threat
exampl
fact
anim
model
autoimmun
predisposit
develop
autoimmun
diseas
follow
adjuv
exposur
mani
recipi
aluminum
contain
adjuv
may
sensit
futur
exposur
siliconinduc
inflammatori
fibro
prolif
respons
irrefut
well
document
presenc
antisilicon
antibodi
siliconeassoci
autoimmun
phenomena
seem
plausibl
asia
syndrom
aluminum
safeti
studi
show
use
aluminum
contain
placebo
control
group
vaccin
safeti
studi
care
evalu
new
studi
must
perform
use
proper
placebo
adequ
test
vaccin
safeti
anoth
evid
failur
vaccin
safeti
studi
shortterm
period
evalu
continu
immun
system
activ
observ
potenti
mechan
diseas
diseas
poorli
understood
far
vaccin
recommend
reassess
frequent
differ
subset
popul
invalid
need
vaccin
howev
lower
possibl
exert
advers
event
easier
potenti
benefit
outweigh
risk
vaccinom
repres
major
breakthrough
vaccin
develop
lead
develop
target
vaccin
peptid
like
immunogen
predict
respons
vaccin
achiev
differenti
host
variabl
achiev
name
genet
pathogen
variabl
develop
vaccin
accordingli
lead
increas
specif
treatment
leav
less
room
advers
event
use
immunomodul
vaccinom
also
give
rise
novel
therapi
autoimmun
diseas
sever
report
case
autoimmun
diseas
follow
vaccin
despit
vitro
posit
result
due
limit
number
case
long
latenc
period
diseas
everi
attempt
epidemiolog
studi
fail
deliv
connect
classif
asia
syndrom
detriment
classic
specif
autoimmun
diseas
could
key
find
effect
prevent
therapeut
strategi
enabl
studi
bigger
patient
cluster
earlier
diagnos
futur
studi
could
help
clarifi
associ
vaccin
adjuv
autoimmun
ideal
differ
design
longterm
data
includ
autoimmun
phenomena
well
largescal
epidemiolog
studi
autoimmun
diseas
